Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Gain Therapeutics, Inc. (GANX)

3.23   0.2 (6.6%) 12-02 15:59
Open: 3.04 Pre. Close: 3.03
High: 3.25 Low: 3.01
Volume: 45,669 Market Cap: 38(M)

Technical analysis

as of: 2022-12-02 4:23:04 PM
Overall:       
Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 4.01     One year: 4.69
Support: Support1: 3.14    Support2: 2.96
Resistance: Resistance1: 3.44    Resistance2: 4.01
Pivot: 3.1
Moving Average: MA(5): 3.09     MA(20): 3.09
MA(100): 3.49     MA(250): 3.78
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 40.4     %D(3): 30.3
RSI: RSI(14): 56.6
52-week: High: 6.69  Low: 2.32
Average Vol(K): 3-Month: 27 (K)  10-Days: 15 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GANX ] has closed It is unclear right now based on current values. 62.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.25 - 3.27 3.27 - 3.28
Low: 2.97 - 2.99 2.99 - 3.01
Close: 3.2 - 3.23 3.23 - 3.25

Company Description

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.

Headline News

Mon, 28 Nov 2022
Monday’s Top Analyst Upgrades and Downgrades: Activision Blizzard, Amazon, Deere, DraftKings, Meta Platforms, Redfin, Tyson Foods, Visa, Wynn Resorts and More - 24/7 Wall St.

Fri, 25 Nov 2022
Health Care Sector Update for 11/25/2022: SPPI,GANX,IINN - Nasdaq

Thu, 10 Nov 2022
Gain Therapeutics, Inc. (GANX) Reports Q3 Loss, Lags Revenue Estimates - Nasdaq

Fri, 04 Nov 2022
Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Lag Estimates - Nasdaq

Mon, 26 Sep 2022
Gain Therapeutics Presents New Preclinical Data Showing Promising Pharmacological Activity in Parkinson’s Disease Patient-Derived Dopaminergic Neurons - Yahoo Finance

Tue, 20 Sep 2022
Gain Therapeutics Announces Promotion of Matthias Alder to Chief Executive Officer - Yahoo Finance

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 12 (M)
% Held by Insiders 8.74e+006 (%)
% Held by Institutions 24.3 (%)
Shares Short 65 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -1.637e+007
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -10
Return on Assets (ttm) 787.9
Return on Equity (ttm) -29
Qtrly Rev. Growth 152250
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.03
Qtrly Earnings Growth -1.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 393.2
Price to Cash Flow 0

Stock Dividends

Dividend 0
Forward Dividend 48380
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.